Skip to main content
Top

03-02-2025 | Praziquantel | Review Article

Therapeutic challenges of schistosomiasis: mechanisms of action and current limitations

Authors: Abdelaali Balahbib, Nasreddine El Omari, Hajar Lghazi, Kenza Hatoufi, Yassin El Atki, Abdelhakim Bouyahya, Fatima Amarir

Published in: Journal of Parasitic Diseases

Login to get access

Abstract

Schistosomiasis, a parasitic disease caused by Schistosoma species, affects millions of people worldwide. This review explores the therapeutic challenges of schistosomiasis, focusing on the mechanisms of action of current treatments and their limitations. Praziquantel, the standard therapy, induces lesions and muscle contractions in the parasites, thereby facilitating their clearance by the host immune system. However, the biological complexity of schistosomes and their ability to modulate the immune response present hurdles to sustained treatment efficacy. Challenges include the emergence of resistance, adverse side effects, and inconsistent cure rates. Additionally, the remarkable longevity of schistosomes—spanning years to decades—complicates the evaluation of treatment outcomes. Addressing these issues, requires ongoing surveillance, research into novel therapeutic agents, and an integrated approach that combines medical interventions with preventive measures. This paper underscores the importance of understanding schistosome biology and advocates for comprehensive strategies to improve the management and control of this debilitating parasitic infection.
Literature
go back to reference Abdel Aziz N, Tallima H, Abou El Dahab M, El Ridi R (2019) Immunogenicity and protective capacity of Schistosoma haematobium recombinant cathepsin L against infection of hamsters with S. haematobium. Vaccine Res 6:1–8CrossRef Abdel Aziz N, Tallima H, Abou El Dahab M, El Ridi R (2019) Immunogenicity and protective capacity of Schistosoma haematobium recombinant cathepsin L against infection of hamsters with S. haematobium. Vaccine Res 6:1–8CrossRef
go back to reference Ahmad I, Ahmad T, Usmanghani K (1991) Oxamniquine. In: Florey K (ed) Analytical profiles of drug substances. Academic Press, pp 601–625 Ahmad I, Ahmad T, Usmanghani K (1991) Oxamniquine. In: Florey K (ed) Analytical profiles of drug substances. Academic Press, pp 601–625
go back to reference Alwan SN, Taylor AB, Rhodes J et al (2023) Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis. PLoS Pathog 19:e1011018PubMedPubMedCentralCrossRef Alwan SN, Taylor AB, Rhodes J et al (2023) Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis. PLoS Pathog 19:e1011018PubMedPubMedCentralCrossRef
go back to reference Amarir F, El Mansouri B, Fellah H et al (2011) National serologic survey of Haematobium schistosomiasis in Morocco: evidence for elimination. Am J Trop Med Hyg 84:15PubMedPubMedCentralCrossRef Amarir F, El Mansouri B, Fellah H et al (2011) National serologic survey of Haematobium schistosomiasis in Morocco: evidence for elimination. Am J Trop Med Hyg 84:15PubMedPubMedCentralCrossRef
go back to reference Aragon AD, Imani RA, Blackburn VR et al (2009) Towards an understanding of the mechanism of action of praziquantel. Mol Biochem Parasitol 164:57–65PubMedCrossRef Aragon AD, Imani RA, Blackburn VR et al (2009) Towards an understanding of the mechanism of action of praziquantel. Mol Biochem Parasitol 164:57–65PubMedCrossRef
go back to reference Asuming-Brempong EK, Ayi I, van der Puije W et al (2022) Increased ShTAL1 IgE responses post-praziquantel treatment may be associated with a reduced risk to re-infection in a Ghanaian S. haematobium-endemic community. PLoS Negl Trop Dis 16:e0010115PubMedPubMedCentralCrossRef Asuming-Brempong EK, Ayi I, van der Puije W et al (2022) Increased ShTAL1 IgE responses post-praziquantel treatment may be associated with a reduced risk to re-infection in a Ghanaian S. haematobium-endemic community. PLoS Negl Trop Dis 16:e0010115PubMedPubMedCentralCrossRef
go back to reference Baron E (1939) Aspiration for removal of biopsy material from the liver: report of thirty-five cases. Arch Intern Med 63:276–289CrossRef Baron E (1939) Aspiration for removal of biopsy material from the liver: report of thirty-five cases. Arch Intern Med 63:276–289CrossRef
go back to reference Bartley PB (2017) Oxamniquine and Metrifonate. Kucers’ the Use of Antibiotics, 7th edn. CRC Bartley PB (2017) Oxamniquine and Metrifonate. Kucers’ the Use of Antibiotics, 7th edn. CRC
go back to reference Bello A, Jimoh AO, Shittu SB, Hudu SA (2014) Prevalence of urinary schistosomiasis and associated haemato-proteinuria in Wurno Rural Area of Sokoto State, Nigeria. Orient J Med 26:114–121 Bello A, Jimoh AO, Shittu SB, Hudu SA (2014) Prevalence of urinary schistosomiasis and associated haemato-proteinuria in Wurno Rural Area of Sokoto State, Nigeria. Orient J Med 26:114–121
go back to reference Borhani M, Mohammadi MA, Entezami M et al (2024) Reinfection of farm dogs following praziquantel treatment in an endemic region of cystic echinococcosis in southeastern Iran. PLoS Negl Trop Dis 18:e0011939PubMedPubMedCentralCrossRef Borhani M, Mohammadi MA, Entezami M et al (2024) Reinfection of farm dogs following praziquantel treatment in an endemic region of cystic echinococcosis in southeastern Iran. PLoS Negl Trop Dis 18:e0011939PubMedPubMedCentralCrossRef
go back to reference Borrego-Sánchez A, Sánchez-Espejo R, García-Villén F et al (2020) Praziquantel–clays as accelerated release systems to enhance the low solubility of the drug. Pharmaceutics 12:914PubMedPubMedCentralCrossRef Borrego-Sánchez A, Sánchez-Espejo R, García-Villén F et al (2020) Praziquantel–clays as accelerated release systems to enhance the low solubility of the drug. Pharmaceutics 12:914PubMedPubMedCentralCrossRef
go back to reference Cioli D (2000) Praziquantel: is there real resistance and are there alternatives? Curr Opin Infect Dis 13:659PubMedCrossRef Cioli D (2000) Praziquantel: is there real resistance and are there alternatives? Curr Opin Infect Dis 13:659PubMedCrossRef
go back to reference D’Abbrunzo I, Voinovich D, Perissutti B (2024) Mechanochemical synthesis of praziquantel hemihydrate in the presence of five solvents with different water miscibility. Crystals 14:374CrossRef D’Abbrunzo I, Voinovich D, Perissutti B (2024) Mechanochemical synthesis of praziquantel hemihydrate in the presence of five solvents with different water miscibility. Crystals 14:374CrossRef
go back to reference da Paixão Siqueira L, Fontes DAF, Aguilera CSB et al (2017) Schistosomiasis: drugs used and treatment strategies. Acta Trop 176:179–187CrossRef da Paixão Siqueira L, Fontes DAF, Aguilera CSB et al (2017) Schistosomiasis: drugs used and treatment strategies. Acta Trop 176:179–187CrossRef
go back to reference Dinnik JA, Dinnik NN (1954) The life cycle of Paramphistomum microbothrium Fischoeder, 1901 (Trematoda, Paramphistomidae). Parasitology 44:285–299PubMedCrossRef Dinnik JA, Dinnik NN (1954) The life cycle of Paramphistomum microbothrium Fischoeder, 1901 (Trematoda, Paramphistomidae). Parasitology 44:285–299PubMedCrossRef
go back to reference Duarte DB, De Francesco Daher E, Pinheiro ME, Oliveira MJC (2020) Schistosomiasis Mansoni-associated kidney disease. In: Bezerra da Silva Junior G, De Francesco Daher E, Barros E, Bezerra da Silva (eds) Tropical nephrology. Springer, Cham, pp 113–129CrossRef Duarte DB, De Francesco Daher E, Pinheiro ME, Oliveira MJC (2020) Schistosomiasis Mansoni-associated kidney disease. In: Bezerra da Silva Junior G, De Francesco Daher E, Barros E, Bezerra da Silva (eds) Tropical nephrology. Springer, Cham, pp 113–129CrossRef
go back to reference Engels D, Chitsulo L, Montresor A, Savioli L (2002) The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Trop 82:139–146PubMedPubMedCentralCrossRef Engels D, Chitsulo L, Montresor A, Savioli L (2002) The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Trop 82:139–146PubMedPubMedCentralCrossRef
go back to reference Fallon PG, Sturrock RF, Niang AC, Doenhoff MJ (1995) Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg 53:61–62PubMedCrossRef Fallon PG, Sturrock RF, Niang AC, Doenhoff MJ (1995) Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg 53:61–62PubMedCrossRef
go back to reference Fenwick A, Rollinson D, Southgate V (2006) Implementation of human schistosomiasis control: challenges and prospects. Adv Parasitol 61:567–622PubMedCrossRef Fenwick A, Rollinson D, Southgate V (2006) Implementation of human schistosomiasis control: challenges and prospects. Adv Parasitol 61:567–622PubMedCrossRef
go back to reference Ferrari MLA, Coelho PMZ, Antunes CMF et al (2003) Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. Bull World Health Organ 81:190–196PubMedPubMedCentral Ferrari MLA, Coelho PMZ, Antunes CMF et al (2003) Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. Bull World Health Organ 81:190–196PubMedPubMedCentral
go back to reference Galaktionov KV, Dobrovolskij A (2013) The biology and evolution of trematodes: an essay on the biology, morphology, life cycles, transmissions, and evolution of digenetic trematodes. Springer Galaktionov KV, Dobrovolskij A (2013) The biology and evolution of trematodes: an essay on the biology, morphology, life cycles, transmissions, and evolution of digenetic trematodes. Springer
go back to reference Gobbi F, Tamarozzi F, Buonfrate D et al (2020) New insights on acute and chronic schistosomiasis: do we need a redefinition? Trends Parasitol 36:660–667PubMedCrossRef Gobbi F, Tamarozzi F, Buonfrate D et al (2020) New insights on acute and chronic schistosomiasis: do we need a redefinition? Trends Parasitol 36:660–667PubMedCrossRef
go back to reference Gupta A, Baker C, Wang H et al (2021) Target animal safety evaluation of a novel topical combination of esafoxolaner, eprinomectin and praziquantel for cats. Parasite 28 Gupta A, Baker C, Wang H et al (2021) Target animal safety evaluation of a novel topical combination of esafoxolaner, eprinomectin and praziquantel for cats. Parasite 28
go back to reference Horák P, Kolářová L, Adema CM (2002) Biology of the schistosome genus Trichobilharzia Horák P, Kolářová L, Adema CM (2002) Biology of the schistosome genus Trichobilharzia
go back to reference Hotez PJ, Lo NC (2020) 27 - neglected tropical diseases: public health control programs and mass drug administration. In: Ryan ET, Hill DR, Solomon T et al (eds) Hunter’s tropical medicine and emerging infectious diseases, 10 edn. Elsevier, London, pp 209–213CrossRef Hotez PJ, Lo NC (2020) 27 - neglected tropical diseases: public health control programs and mass drug administration. In: Ryan ET, Hill DR, Solomon T et al (eds) Hunter’s tropical medicine and emerging infectious diseases, 10 edn. Elsevier, London, pp 209–213CrossRef
go back to reference Jaoko WG, Muchemi G, Oguya FO (1996) Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya. East Afr Med J 73:499–501PubMed Jaoko WG, Muchemi G, Oguya FO (1996) Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya. East Afr Med J 73:499–501PubMed
go back to reference Kaji MD (2020) Investigating the role of species differences and subunit isoforms in sensitivity towards drugs that target nematode ligand-gated ion channels. McGill University, Canada Kaji MD (2020) Investigating the role of species differences and subunit isoforms in sensitivity towards drugs that target nematode ligand-gated ion channels. McGill University, Canada
go back to reference Karunamoorthi K, Almalki MJ, Ghailan KY (2018) Schistosomiasis: a neglected tropical disease of poverty: a call for intersectoral mitigation strategies for better health. J Health Res Rev Dev Ctries 5:1–12 Karunamoorthi K, Almalki MJ, Ghailan KY (2018) Schistosomiasis: a neglected tropical disease of poverty: a call for intersectoral mitigation strategies for better health. J Health Res Rev Dev Ctries 5:1–12
go back to reference Keiser J, Utzinger J (2012) Antimalarials in the treatment of schistosomiasis. Curr Pharm Des 18:3531–3538PubMed Keiser J, Utzinger J (2012) Antimalarials in the treatment of schistosomiasis. Curr Pharm Des 18:3531–3538PubMed
go back to reference King CH (2011) Schistosomiasis: challenges and opportunities. Causes Impacts Neglected Trop Zoonotic Dis Oppor Integr Interv Strateg King CH (2011) Schistosomiasis: challenges and opportunities. Causes Impacts Neglected Trop Zoonotic Dis Oppor Integr Interv Strateg
go back to reference Kirubi ME (2020) Efficacy and safety of up-scaled dosage of 60 Mg/Kg praziquantel in control of schistosoma Mansoni in School Going Children in Kirinyaga County, Kenya. Thesis, JKUAT-COHES Kirubi ME (2020) Efficacy and safety of up-scaled dosage of 60 Mg/Kg praziquantel in control of schistosoma Mansoni in School Going Children in Kirinyaga County, Kenya. Thesis, JKUAT-COHES
go back to reference Kogiannou D, Nikoloudaki C, Rigos G (2021) Absorption and depletion of dietary administered praziquantel in greater amberjack, Seriola dumerili. Aquaculture 535:736354CrossRef Kogiannou D, Nikoloudaki C, Rigos G (2021) Absorption and depletion of dietary administered praziquantel in greater amberjack, Seriola dumerili. Aquaculture 535:736354CrossRef
go back to reference Kohn AB, Anderson PA, Roberts-Misterly JM, Greenberg RM (2001) Schistosome calcium channel β subunits: unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. J Biol Chem 276:36873–36876PubMedCrossRef Kohn AB, Anderson PA, Roberts-Misterly JM, Greenberg RM (2001) Schistosome calcium channel β subunits: unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. J Biol Chem 276:36873–36876PubMedCrossRef
go back to reference Kopperstad CC (2017) Schistosoma life cycle-facts and remaining questions. Master’s Thesis Kopperstad CC (2017) Schistosoma life cycle-facts and remaining questions. Master’s Thesis
go back to reference Lalthanpuii PB, Zokimi Z, Lalchhandama K (2020) Anthelmintic activity of praziquantel and Spilanthes acmella extract on an intestinal cestode parasite. Acta Pharm 70:551–560PubMedCrossRef Lalthanpuii PB, Zokimi Z, Lalchhandama K (2020) Anthelmintic activity of praziquantel and Spilanthes acmella extract on an intestinal cestode parasite. Acta Pharm 70:551–560PubMedCrossRef
go back to reference Lebens M, Sun J-B, Czerkinsky C, Holmgren J (2004) Current status and future prospects for a vaccine against schistosomiasis. Expert Rev Vaccines Lebens M, Sun J-B, Czerkinsky C, Holmgren J (2004) Current status and future prospects for a vaccine against schistosomiasis. Expert Rev Vaccines
go back to reference Lee BY, Bartsch SM, Gorham KM (2015) Chapter eight - economic and financial evaluation of neglected tropical diseases. In: Anderson RM, Basáñez MG (eds) Advances in parasitology. Academic Press, pp 329–417 Lee BY, Bartsch SM, Gorham KM (2015) Chapter eight - economic and financial evaluation of neglected tropical diseases. In: Anderson RM, Basáñez MG (eds) Advances in parasitology. Academic Press, pp 329–417
go back to reference Lespine A, Alvinerie M, Vercruysse J et al (2008) ABC transporter modulation: a strategy to enhance the activity of macrocyclic lactone anthelmintics. Trends Parasitol 24:293–298PubMedCrossRef Lespine A, Alvinerie M, Vercruysse J et al (2008) ABC transporter modulation: a strategy to enhance the activity of macrocyclic lactone anthelmintics. Trends Parasitol 24:293–298PubMedCrossRef
go back to reference Levecke B, Vlaminck J, Andriamaro L et al (2020) Evaluation of the therapeutic efficacy of praziquantel against schistosomes in seven countries with ongoing large-scale deworming programs. Int J Parasitol Drugs Drug Resist 14:183–187PubMedPubMedCentralCrossRef Levecke B, Vlaminck J, Andriamaro L et al (2020) Evaluation of the therapeutic efficacy of praziquantel against schistosomes in seven countries with ongoing large-scale deworming programs. Int J Parasitol Drugs Drug Resist 14:183–187PubMedPubMedCentralCrossRef
go back to reference Lightowlers MW, Gasser RB, Hemphill A et al (2021) Advances in the treatment, diagnosis, control and scientific understanding of taeniid cestode parasite infections over the past 50 years. Int J Parasitol 51:1167–1192PubMedCrossRef Lightowlers MW, Gasser RB, Hemphill A et al (2021) Advances in the treatment, diagnosis, control and scientific understanding of taeniid cestode parasite infections over the past 50 years. Int J Parasitol 51:1167–1192PubMedCrossRef
go back to reference Loker ES, DeJong RJ, Brant SV (2022) Scratching the itch: updated perspectives on the Schistosomes responsible for swimmer’s itch around the World. Pathogens 11:587PubMedPubMedCentralCrossRef Loker ES, DeJong RJ, Brant SV (2022) Scratching the itch: updated perspectives on the Schistosomes responsible for swimmer’s itch around the World. Pathogens 11:587PubMedPubMedCentralCrossRef
go back to reference Lombardo FC, Pasche V, Panic G et al (2019) Life cycle maintenance and drug-sensitivity assays for early drug discovery in Schistosoma mansoni. Nat Protoc 14:461–481PubMedCrossRef Lombardo FC, Pasche V, Panic G et al (2019) Life cycle maintenance and drug-sensitivity assays for early drug discovery in Schistosoma mansoni. Nat Protoc 14:461–481PubMedCrossRef
go back to reference LoVerde PT, Alwan SN, Taylor AB et al (2021) Rational approach to drug discovery for human schistosomiasis. Int J Parasitol Drugs Drug Resist 16:140–147PubMedPubMedCentralCrossRef LoVerde PT, Alwan SN, Taylor AB et al (2021) Rational approach to drug discovery for human schistosomiasis. Int J Parasitol Drugs Drug Resist 16:140–147PubMedPubMedCentralCrossRef
go back to reference Mahanta J (2022) Paragonimiasis. In: Parija SC, Chaudhury A (eds) Textbook of parasitic zoonoses. Springer, Singapore, pp 245–258CrossRef Mahanta J (2022) Paragonimiasis. In: Parija SC, Chaudhury A (eds) Textbook of parasitic zoonoses. Springer, Singapore, pp 245–258CrossRef
go back to reference Mahmoud AA (2001) Schistosomiasis. World Scientific Mahmoud AA (2001) Schistosomiasis. World Scientific
go back to reference McManus JF, Costa K, Ng HC et al (2018) Time-series transects of deglacial circulation changes in the Deep North Atlantic Ocean. In: AGU fall meeting abstracts, pp PP13A-08 McManus JF, Costa K, Ng HC et al (2018) Time-series transects of deglacial circulation changes in the Deep North Atlantic Ocean. In: AGU fall meeting abstracts, pp PP13A-08
go back to reference McTigue MA, Williams DR, Tainer JA (1995) Crystal structures of a schistosomal drug and vaccine target: glutathione S-transferase fromschistosoma japonicaand its complex with the leading antischistomal drug praziquantel. J Mol Biol 246:21–27PubMedCrossRef McTigue MA, Williams DR, Tainer JA (1995) Crystal structures of a schistosomal drug and vaccine target: glutathione S-transferase fromschistosoma japonicaand its complex with the leading antischistomal drug praziquantel. J Mol Biol 246:21–27PubMedCrossRef
go back to reference Melman SD, Steinauer ML, Cunningham C et al (2009) Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 3:e504PubMedPubMedCentralCrossRef Melman SD, Steinauer ML, Cunningham C et al (2009) Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 3:e504PubMedPubMedCentralCrossRef
go back to reference Molehin AJ (2020a) Current understanding of immunity against Schistosomiasis: impact on Vaccine and Drug Development. Res Rep Trop Med Molehin AJ (2020a) Current understanding of immunity against Schistosomiasis: impact on Vaccine and Drug Development. Res Rep Trop Med
go back to reference Mukherjee S, Mukherjee N, Gayen P et al (2016) Metabolic inhibitors as antiparasitic drugs: pharmacological, biochemical and molecular perspectives. Curr Drug Metab 17:937–970PubMedCrossRef Mukherjee S, Mukherjee N, Gayen P et al (2016) Metabolic inhibitors as antiparasitic drugs: pharmacological, biochemical and molecular perspectives. Curr Drug Metab 17:937–970PubMedCrossRef
go back to reference Neves MI, Milne GC, Webster JP, Walker M (2024) Socio-ecological heterogeneity and uncertainty in the elimination of human schistosomiasis. medRxiv 2024–03 Neves MI, Milne GC, Webster JP, Walker M (2024) Socio-ecological heterogeneity and uncertainty in the elimination of human schistosomiasis. medRxiv 2024–03
go back to reference Norbury LJ, Shirakashi S, Power C et al (2022) Praziquantel use in aquaculture–current status and emerging issues. Int J Parasitol Drugs Drug Resist 18:87–102PubMedPubMedCentralCrossRef Norbury LJ, Shirakashi S, Power C et al (2022) Praziquantel use in aquaculture–current status and emerging issues. Int J Parasitol Drugs Drug Resist 18:87–102PubMedPubMedCentralCrossRef
go back to reference Obonyo MD (1981) Epidemiology and urological complications of schistosomiasis haematobium. Thesis Obonyo MD (1981) Epidemiology and urological complications of schistosomiasis haematobium. Thesis
go back to reference OMS OWH (1985) Lutte contre la schistosomiase: rapport d’un Comité OMS d’experts [réuni à Genève du 8 au 13 novembre 1984] OMS OWH (1985) Lutte contre la schistosomiase: rapport d’un Comité OMS d’experts [réuni à Genève du 8 au 13 novembre 1984]
go back to reference Paliy AP, Petrov RV, Kovalenko LM et al (2021) Effectiveness of a modern antiparasitic agent for deworming in domestic animals. Ukr J Ecol 11:10–17CrossRef Paliy AP, Petrov RV, Kovalenko LM et al (2021) Effectiveness of a modern antiparasitic agent for deworming in domestic animals. Ukr J Ecol 11:10–17CrossRef
go back to reference Pamu S, Singh T, Chandrudu J (2018) Schistosoma and Human Schistosomiasis. Educreation Publishing Pamu S, Singh T, Chandrudu J (2018) Schistosoma and Human Schistosomiasis. Educreation Publishing
go back to reference Park S-K, Marchant JS (2020) The journey to discovering a flatworm target of praziquantel: a long TRP. Trends Parasitol 36:182–194PubMedCrossRef Park S-K, Marchant JS (2020) The journey to discovering a flatworm target of praziquantel: a long TRP. Trends Parasitol 36:182–194PubMedCrossRef
go back to reference Pica-Mattoccia L, Cioli D (2012) Praziquantel: too good to be replaced? In: Caffrey CR (ed) Parasitic helminths, 1st edn. Wiley, pp 309–321 Pica-Mattoccia L, Cioli D (2012) Praziquantel: too good to be replaced? In: Caffrey CR (ed) Parasitic helminths, 1st edn. Wiley, pp 309–321
go back to reference Pica-Mattoccia L, Cioli D, Archer S (1989) Binding of oxamniquine to the DNA of schistosomes. Trans R Soc Trop Med Hyg 83:373–376PubMedCrossRef Pica-Mattoccia L, Cioli D, Archer S (1989) Binding of oxamniquine to the DNA of schistosomes. Trans R Soc Trop Med Hyg 83:373–376PubMedCrossRef
go back to reference Pillay D (2022) Structural and biophysical characterization of the interaction between Schistosoma mansoni axonemal dynein intermediate chain protein and dynarrestin. PhD Thesis, University of Johannesburg Pillay D (2022) Structural and biophysical characterization of the interaction between Schistosoma mansoni axonemal dynein intermediate chain protein and dynarrestin. PhD Thesis, University of Johannesburg
go back to reference Probst AC (2023) Investigations on new and forgotten antischistosomal drugs and praziquantel pharmacokinetics in opisthorchiasis patients. PhD Thesis, University_of_Basel_Associated_Institution Probst AC (2023) Investigations on new and forgotten antischistosomal drugs and praziquantel pharmacokinetics in opisthorchiasis patients. PhD Thesis, University_of_Basel_Associated_Institution
go back to reference Qian M-B, Patel C, Palmeirim MS et al (2022) Efficacy of drugs against clonorchiasis and opisthorchiasis: a systematic review and network meta-analysis. Lancet Microbe 3:e616–e624PubMedCrossRef Qian M-B, Patel C, Palmeirim MS et al (2022) Efficacy of drugs against clonorchiasis and opisthorchiasis: a systematic review and network meta-analysis. Lancet Microbe 3:e616–e624PubMedCrossRef
go back to reference Redman CA, Robertson A, Fallon PG et al (1996) Praziquantel: an urgent and exciting challenge. Parasitol Today 12:14–20PubMedCrossRef Redman CA, Robertson A, Fallon PG et al (1996) Praziquantel: an urgent and exciting challenge. Parasitol Today 12:14–20PubMedCrossRef
go back to reference Richter J (2022) Current status of the treatment of paragonimiasis. Lung Cancer 8 Richter J (2022) Current status of the treatment of paragonimiasis. Lung Cancer 8
go back to reference Rodríguez-Ruiz C, Salas-Zúñiga R, Sánchez-Guadarrama MO et al (2022) Structural, physicochemical, and biopharmaceutical properties of cocrystals with RS - and R -praziquantelgeneration and prolongation of the supersaturation state in the presence of cellulosic polymers. Cryst Growth Des 22:6023–6038. https://doi.org/10.1021/acs.cgd.2c00661CrossRef Rodríguez-Ruiz C, Salas-Zúñiga R, Sánchez-Guadarrama MO et al (2022) Structural, physicochemical, and biopharmaceutical properties of cocrystals with RS - and R -praziquantelgeneration and prolongation of the supersaturation state in the presence of cellulosic polymers. Cryst Growth Des 22:6023–6038. https://​doi.​org/​10.​1021/​acs.​cgd.​2c00661CrossRef
go back to reference Salas-Coronas J, Vázquez-Villegas J, Lozano-Serrano AB et al (2020) Severe complications of imported schistosomiasis, Spain: a retrospective observational study. Travel Med Infect Dis 35:101508PubMedCrossRef Salas-Coronas J, Vázquez-Villegas J, Lozano-Serrano AB et al (2020) Severe complications of imported schistosomiasis, Spain: a retrospective observational study. Travel Med Infect Dis 35:101508PubMedCrossRef
go back to reference Shao B, Gui X, Lu Z et al (2023) Praziquantel promotes protection against Schistosoma japonicum infection in mice. Acta Trop 241:106874PubMedCrossRef Shao B, Gui X, Lu Z et al (2023) Praziquantel promotes protection against Schistosoma japonicum infection in mice. Acta Trop 241:106874PubMedCrossRef
go back to reference Stothard JR, Sousa-Figueiredo JC, Betson M et al (2013) Schistosomiasis in African infants and preschool children: let them now be treated! Trends Parasitol 29:197–205PubMedPubMedCentralCrossRef Stothard JR, Sousa-Figueiredo JC, Betson M et al (2013) Schistosomiasis in African infants and preschool children: let them now be treated! Trends Parasitol 29:197–205PubMedPubMedCentralCrossRef
go back to reference Thomas CM, Fitzsimmons CM, Dunne DW, Timson DJ (2015) Comparative biochemical analysis of three members of the Schistosoma mansoni TAL family: differences in ion and drug binding properties. Biochimie 108:40–47PubMedPubMedCentralCrossRef Thomas CM, Fitzsimmons CM, Dunne DW, Timson DJ (2015) Comparative biochemical analysis of three members of the Schistosoma mansoni TAL family: differences in ion and drug binding properties. Biochimie 108:40–47PubMedPubMedCentralCrossRef
go back to reference Useh MF (2012) Control of schistosomiasis. Rokni MB Shistosomiasis Croat Rij 73–102 Useh MF (2012) Control of schistosomiasis. Rokni MB Shistosomiasis Croat Rij 73–102
go back to reference Vermaak C, Boshoff C (2022) The Use of Intramuscular Praziquantel in South-African ruminants against Cestode parasites. A first pilot study. Pharmacol Pharm 13:417–428CrossRef Vermaak C, Boshoff C (2022) The Use of Intramuscular Praziquantel in South-African ruminants against Cestode parasites. A first pilot study. Pharmacol Pharm 13:417–428CrossRef
go back to reference Vermund SH, Bradley DJ, Ruiz-Tiben E (1983) Survival of Schistosoma mansoni in the human host. estimates from a community-based prospective study in Puerto Rico Vermund SH, Bradley DJ, Ruiz-Tiben E (1983) Survival of Schistosoma mansoni in the human host. estimates from a community-based prospective study in Puerto Rico
go back to reference Waldeland UK (2017) Schistosoma life cycle-facts and remaining questions. Master’s Thesis Waldeland UK (2017) Schistosoma life cycle-facts and remaining questions. Master’s Thesis
go back to reference Webster JP, Molyneux DH, Hotez PJ, Fenwick A (2014) The contribution of mass drug administration to global health: past, present and future. Philos Trans R Soc B Biol Sci 369:20130434CrossRef Webster JP, Molyneux DH, Hotez PJ, Fenwick A (2014) The contribution of mass drug administration to global health: past, present and future. Philos Trans R Soc B Biol Sci 369:20130434CrossRef
go back to reference Zanolla D, Perissutti B, Passerini N et al (2018) A new soluble and bioactive polymorph of praziquantel. Eur J Pharm Biopharm 127:19–28PubMedCrossRef Zanolla D, Perissutti B, Passerini N et al (2018) A new soluble and bioactive polymorph of praziquantel. Eur J Pharm Biopharm 127:19–28PubMedCrossRef
Metadata
Title
Therapeutic challenges of schistosomiasis: mechanisms of action and current limitations
Authors
Abdelaali Balahbib
Nasreddine El Omari
Hajar Lghazi
Kenza Hatoufi
Yassin El Atki
Abdelhakim Bouyahya
Fatima Amarir
Publication date
03-02-2025
Publisher
Springer India
Published in
Journal of Parasitic Diseases
Print ISSN: 0971-7196
Electronic ISSN: 0975-0703
DOI
https://doi.org/10.1007/s12639-025-01785-4

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more